（文章来源：证券日报） 证券日报网讯 2月26日，康恩贝发布公告称，公司全资子公司浙江金华康恩贝生物制药有限公司近日获 国家药监局核准签发20mg、40mg规格艾司奥美拉唑镁肠溶胶囊《药品注册证书》，视同通过仿制药一 致性评价，已投入研发费用约1240万元，该品种属医保乙类，2024年国内同类胶囊销售额8.15亿元。 ...

根据公告，艾司奥美拉唑镁肠溶片（耐信）是由阿斯利康制药公司研发的首个具有单一光学异构体的质 子泵抑制剂，阿斯利康的耐信于2001年在美国上市，2007年获批进入中国，能有效抑制胃酸分泌，临床 上主要用于治疗胃食管反流病、糜烂性反流性食管炎，以及联合适当抗菌药物根除幽门螺杆菌，从而促 进相关消化性溃疡愈合。 北京商报讯（记者 王寅浩 宋雨盈）2月26日，康恩贝发布公告称，公司全资子公司浙江金华康恩贝生物 制药有限公司收到国家药品监督管理局核准签发的规格为20mg、40mg的艾司奥美拉唑镁肠溶胶囊《药 品注册证书》。 ...

每经AI快讯，2月26日，康恩贝（600572）公告，公司全资子公司浙江金华康恩贝生物制药有限公司收 到国家药品监督管理局签发的艾司奥美拉唑镁肠溶胶囊《药品注册证书》。该产品用于治疗胃食管反流 病、糜烂性反流性食管炎，以及联合适当抗菌药物根除幽门螺杆菌，从而促进相关消化性溃疡愈合。 ...

证券简称：康恩贝 证券代码：600572 编号：2026-016 浙江康恩贝制药股份有限公司 关于子公司艾司奥美拉唑镁肠溶胶囊 获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其 内容的真实性、准确性和完整性承担法律责任。 近日，浙江康恩贝制药股份有限公司（以下简称"公司"）全资子公司浙江金华康恩 贝生物制药有限公司（以下简称"金华康恩贝"）收到国家药品监督管理局（以下简称" 国家药监局"）核准签发的规格为 20mg、40mg 的艾司奥美拉唑镁肠溶胶囊《药品注册证 书》，现将相关情况公告如下： 证书编号：2026S00454，2026S00455 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合药品 注册的有关要求，批准注册，发给药品注册证书。 二、药品其他相关情况 艾司奥美拉唑镁肠溶片（耐信）是由阿斯利康制药公司研发的首个具有单一光学异构 体的质子泵抑制剂，阿斯利康的耐信于 2001 年在美国上市，2007 年获批进入中国，能有 效抑制胃酸分泌，临床上主要用于治疗胃食管反流病、糜烂性反流性食管炎，以及联合适 当抗菌药物根除幽门 ...

格隆汇2月26日丨康恩贝(600572.SH)公布，公司全资子公司浙江金华康恩贝生物制药有限公司（称"金 华康恩贝"）收到国家药品监督管理局核准签发的规格为 20mg、40mg 的艾司奥美拉唑镁肠溶胶囊《药 品注册证书》。 艾司奥美拉唑镁肠溶片（耐信）是由阿斯利康制药公司研发的首个具有单一光学异构体的质子泵抑制 剂，阿斯利康的耐信于 2001 年在美国上市，2007 年获批进入中国，能有效抑制胃酸分泌，临床上主要 用于治疗胃食管反流病、糜烂性反流性食管炎，以及联合适当抗菌药物根除幽门螺杆菌，从而促进相关 消化性溃疡愈合。 ...

Group 1 - Major shareholder Han Yuanfu of Dayuan Pump Industry plans to reduce his stake by up to 3%, totaling no more than 5.595 million shares [1] - Hainan Highway, a shareholder of Haikou Group, intends to increase its stake in the company by no less than 40 million yuan and no more than 50 million yuan [2] - China Communications Construction Company signed new contracts worth 1.883672 trillion yuan in 2025, a year-on-year increase of 0.13% [3] Group 2 - The controlling shareholder of Quzhou Development proposed to repurchase shares worth between 100 million and 200 million yuan [4] - Shareholder Huang Song of Huibo Pu plans to reduce his stake by up to 1%, totaling no more than 1.3372 million shares [5] - The board secretary of Fusenmei has had his detention lifted and is now under investigation, allowing him to resume his duties [6] Group 3 - YN Holdings clarified that its investment target does not belong to the sectors of computing chip manufacturing, computing leasing, or cloud services [7] - Shareholder Euro Star Diamond plans to reduce its stake in Laishen Tongling by up to 3%, totaling no more than 1.029 million shares [8] - Shareholder Zhu Guangkui of Demar Technology plans to reduce his stake by up to 3%, totaling no more than 791.24 million shares [10] Group 4 - Newnow's subsidiary received approval for clinical trials of drug SYS6023 for breast cancer treatment [11] - Ruipubio plans to invest 295 million yuan to establish a merger and acquisition industry fund focusing on animal health and biomedicine [12] - Shareholder Ningbo Hutong plans to reduce its stake in Huitong Energy by up to 1%, totaling no more than 206.28 million shares [13] Group 5 - Chengda Bio's high-dose influenza virus vaccine has received approval for clinical trials [14] - Kang En Bei's subsidiaries participated in the national centralized procurement process, with selected drugs expected to generate 385 million yuan in sales in 2024 [15] - Weitang Industrial signed a strategic cooperation framework agreement with Amphenol to enhance product development and market collaboration [16] Group 6 - Terui De is the first candidate for a 137 million yuan EPC general contracting project [17] - Chen Zhan Optoelectronics plans to invest 650 million yuan to establish an overseas smart manufacturing base [19] - Zhang Yi Technology's AI short drama business revenue is expected to account for no more than 1% of total revenue in 2025 [20] Group 7 - Jiangshan Co. plans to reduce its stake by up to 3%, totaling no more than 4.3308 million shares [21] - Xie Chuang Data plans to procure servers from multiple suppliers, with a total expected expenditure of no more than 11 billion yuan [22] - Huaming Equipment is planning to issue H-shares and list on the Hong Kong Stock Exchange [23] Group 8 - Wenzhou Hongfeng plans to raise no more than 450 million yuan through a private placement for expansion projects [24] - Yingkerui plans to raise no more than 379 million yuan for various projects including smart power supply systems [25] - Jingrui Electric Materials plans to invest 600 million yuan to build a key materials base for the integrated circuit manufacturing industry [26] Group 9 - Beijing Bank's chairman resigned due to age [27] - Youkeshu's actual controller plans to increase his stake by no less than 50 million yuan and no more than 100 million yuan [28] - Hanbo High-tech's subsidiary plans to acquire assets to enter the wet electronic chemicals industry [29] Group 10 - Jia Mei Packaging clarified that its capital operations related to Magic Atom will be independent of the listed company [30] - International Composite Materials confirmed that electronic-grade glass fiber is a key raw material for PCBs [31] - Zhongyin Fashion plans to procure hardware simulation accelerators for 9.385 million USD [32] Group 11 - Haohai Biotechnology's shareholder plans to reduce his stake by up to 0.4337% [33] - United Optoelectronics plans to sign a framework contract with Lingzhi Cloud Creation for robot assembly services [34] - Qianfang Technology's major shareholder plans to reduce its stake by up to 1.5%, totaling no more than 2.36507 million shares [35] Group 12 - Xiamen Airport plans to acquire 100% of Zhaoxiang Technology for 1.193 billion yuan [36] - Tuoshan Heavy Industry plans to acquire 51% of Xin Kaiyuan for 219 million yuan [38] - Shenkai Co. plans to repurchase shares worth between 40 million and 80 million yuan [39] Group 13 - Hushun Co. plans to invest 3.3 billion yuan in a high-end PCB production project [40] - Zhengzhou Bank appointed Wang Sentao as vice president, pending regulatory approval [41]

Core Viewpoint - Zhejiang Kangnbei Pharmaceutical Co., Ltd. announced that its subsidiaries have been selected for the continuation procurement of certain drugs under the national organized procurement program, which is expected to positively impact the company's sales and market share [1][2]. Group 1: Selected Drugs Information - The company’s subsidiaries participated in the national organized procurement for the continuation of drugs, with 11 products including Tamsulosin Hydrochloride Sustained-Release Capsules and Piperacillin Sodium and Tazobactam Sodium for Injection being selected [1]. - The procurement period for the selected drugs will last until December 31, 2028, starting from the implementation of the selection results [1]. Group 2: Financial Impact - The total sales revenue from the selected drugs for 2024 is projected to be 385.29 million, accounting for 5.91% of the company's total revenue of 6.52 billion for the same year [2]. - For the first three quarters of 2025, the projected sales revenue from these drugs is 296.15 million, representing 5.95% of the company's revenue of 4.98 billion [2]. - The selected drugs are expected to maintain stable or declining prices, which will help the company expand sales and enhance brand influence [2].

Group 1 - Jia Mei Packaging announced that the capital operation plan related to Magic Atom will be completely independent of the listed company, with no injection plan [2] - Shuangliang Energy indirectly participates in commercial aerospace projects but does not have direct cooperation with SpaceX [2] - Zhangyue Technology expects that the revenue from its AI short drama business in 2025 will not exceed 1% of its total annual revenue [2] Group 2 - Xianglu Tungsten stated that significant economic fluctuations in the countries of its main customers could greatly impact the demand for tungsten products and the recovery of accounts receivable [3] - United Optoelectronics signed a business cooperation framework contract with Lingzhi Cloud Creation to provide assembly and processing services for robot products [4] - Hanbo High-tech's subsidiary plans to acquire assets to layout the wet electronic chemicals industry [4] Group 3 - International Composite Materials confirmed that electronic-grade glass fiber is a key raw material for PCBs and that its operations are normal [5] - Jingrui Electric Materials plans to invest 600 million yuan to build a comprehensive base for key materials in the integrated circuit manufacturing industry in the western region [6] - Wenzhou Hongfeng intends to raise no more than 450 million yuan for the expansion of lithium battery copper foil and electronic copper foil projects [7] Group 4 - Zhi Chuang Data plans to procure servers from multiple suppliers, with a total expected amount not exceeding 11 billion yuan [8] - Zhangyuan Tungsten reported that its current operating conditions and external environment are normal, with no undisclosed significant matters [17] - Yida Co. plans to adjust the technical reform project for the production of 220,000 tons of epoxy propylene derivatives [19] Group 5 - Huazhong Bank reported a net profit of 27.2 billion yuan for 2025, a decrease of 1.72% year-on-year [27][28] - Jin Dike reported a net loss of 173 million yuan for 2025, despite a revenue increase of 40.13% [29] - Luan An Huan Neng reported a 16.8% year-on-year increase in coal sales in January 2026 [30]

Core Viewpoint - The company, Kangnibei, anticipates that its export business will account for approximately 8% of total revenue in 2024, focusing on regions such as India, the Middle East, Pakistan, and Europe [2] Group 1 - The export products primarily include active pharmaceutical ingredients such as Azithromycin, Amikacin Sulfate, Dexamethasone Hydrochloride, and Clarithromycin [2]

证券日报网讯 2月12日，康恩贝在互动平台回答投资者提问时表示，关于新药研发进展方面，公司重视 产品创新与研发，2025年上半年公司已推进EVT401和洋常春藤提取物及口服液项目进入II期临床。近 日，公司TFA003片也获得药物临床试验批准通知书，同意开展用于糖尿病肾脏疾病的临床试验。未来 公司将持续推进创新药研发、仿制药布局及优势大品种二次开发，不断丰富产品矩阵，优化产品结构， 提升核心竞争力与可持续发展能力。相关进展请以公司正式披露信息为准。 （文章来源：证券日报） ...